$Cross Country Healthcare (CCRN.US)$ 🎯 2024.4.10 Current pr...

New data: 23Q4, continued overall contraction.

In 2023, revenue shrank by 28%, operating profit shrank by 54.6% due to the increase in the share of expenses, and net profit shrank 61.5%.

The balance ratio fell from 51.8% to 30.3%, total assets fell sharply, and net assets increased slightly. Asset-side accounts receivable have been drastically reduced, long-term loans of 150 million dollars have been eliminated on the debt side, and accounts payable have also been drastically reduced. Overall, there has been a leverage-reduction response to the contraction of the business.

Net cash flow from operations was significantly higher than net investment, generating large shareholders' surpluses.

Currently, the price-earnings ratio is 8.6. The valuation is unattractive compared to the current shrinking trend. There is no need to adjust if you only hold a small number of observation positions.